✦ LIBER ✦

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial

✍ Scribed by John A Ormiston; Patrick W Serruys; Evelyn Regar; Dariusz Dudek; Leif Thuesen; Mark WI Webster; Yoshinobu Onuma; Hector M Garcia-Garcia; Robert McGreevy; Susan Veldhof

Book ID: 117302652
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 399 KB
Volume: 371
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)60415-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Prospective, Randomized Evaluation of

A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary Stent: The PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) Trial

✍ Gregg W. Stone; Paul S. Teirstein; Ian T. Meredith; Bruno Farah; Christophe L. D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 825 KB

Four-year clinical follow-up of the XIEN

Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial

✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB

Comparison of Everolimus- and Sirolimus-

Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Long Coronary Artery Lesions: A Randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial

✍ Duk-Woo Park; Young-Hak Kim; Hae-Geun Song; Jung-Min Ahn; Won-Jang Kim; Jong-You 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 516 KB

Five-year long-term clinical follow-up o

Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial

✍ Marcus Wiemer; Patrick W. Serruys; Karine Miquel-Hebert; Franz-Josef Neumann; Ja 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 2 views

ABSORB II randomized controlled trial: A

ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design

✍ Roberto Diletti; Patrick W. Serruys; Vasim Farooq; Krishnankutty Sudhir; Cecile 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 419 KB